Evolus Dermal Filler Evolysse Lift Meets Primary Endpoint, Demonstrates Superiority To Restylane-L At 6 Months; Shows Statistically Significant Improvement In Nasolabial Fold Severity Compared To Restylane-L At All Timepoints Over 12 Months
Portfolio Pulse from Benzinga Newsdesk
Evolus' dermal filler Evolysse Lift has met its primary endpoint, demonstrating superiority to Restylane-L at 6 months and showing statistically significant improvement in nasolabial fold severity compared to Restylane-L at all timepoints over 12 months.
May 20, 2024 | 12:31 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Evolus' Evolysse Lift has demonstrated superior performance to Restylane-L in clinical trials, showing significant improvement in nasolabial fold severity over 12 months. This positive outcome could boost investor confidence and drive the stock price up in the short term.
The clinical trial results showing Evolysse Lift's superiority to a well-known competitor like Restylane-L are likely to enhance investor confidence in Evolus' product portfolio, potentially driving the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100